Sumitomo Mitsui DS Asset Management Company Ltd Buys 306 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,969 shares of the company’s stock after acquiring an additional 306 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $2,881,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. APEIRON CAPITAL Ltd grew its holdings in Moderna by 96.2% during the 4th quarter. APEIRON CAPITAL Ltd now owns 31,200 shares of the company’s stock worth $3,103,000 after acquiring an additional 15,300 shares during the last quarter. Lindbrook Capital LLC lifted its position in Moderna by 41.9% during the 4th quarter. Lindbrook Capital LLC now owns 1,391 shares of the company’s stock valued at $138,000 after purchasing an additional 411 shares during the period. abrdn plc lifted its position in Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares during the period. J.W. Cole Advisors Inc. lifted its position in Moderna by 8.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 2,222 shares of the company’s stock valued at $221,000 after purchasing an additional 174 shares during the period. Finally, Wetzel Investment Advisors Inc. acquired a new position in Moderna during the 4th quarter valued at about $347,000. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research reports. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a research report on Tuesday, January 2nd. Canaccord Genuity Group upped their target price on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Royal Bank of Canada restated an “outperform” rating and set a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Finally, HSBC reiterated a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $126.49.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at approximately $406,651. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,954 shares of company stock worth $11,533,976. Company insiders own 15.20% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $107.89 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company has a market capitalization of $41.31 billion, a P/E ratio of -8.69 and a beta of 1.62. The company’s 50 day moving average price is $101.39 and its two-hundred day moving average price is $93.53. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s quarterly revenue was down 44.9% on a year-over-year basis. During the same period last year, the company posted $3.61 EPS. On average, analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.